Home > Gastroenterology > Cobitolimod might induce remission in moderate-to-severe left-sided ulcerative colitis

Cobitolimod might induce remission in moderate-to-severe left-sided ulcerative colitis


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22
Journal
Lancet Gastroenterology and Hepatology
Reuters Health - 26/10/2020 - Topically administered cobitolimod may induce remission in patients with moderate-to-severe left-sided ulcerative colitis (UC), according to results from the phase-2b CONDUCT trial. "Only two local applications of 250 mg cobitolimod, three weeks apart, led to induction of clinical remission already at week 6 in this moderate-to-severe, treatment-refractory ulcerative colitis patient population," Dr. Raja Atreya of University Hospital Erlangen, in Germany, told Reuters Health by email. But outside experts warn that the findings may not pan out. "In previous years, many encouraging compounds that showed positive results in phase 1 or 2 studies have not delivered in phase 3 development programs," write Dr. Christopher Ma and Dr. Remo Panaccione of the University of Calgary, in Alberta, Canada, in a linked editorial. "This risk for cobitolimod is particularly high given that important secondary endpoints, including differences in end...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on